{
    "nctId": "NCT06330012",
    "briefTitle": "The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.",
    "officialTitle": "Spatial Transcriptomic Approach for Revealing the Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.",
    "overallStatus": "RECRUITING",
    "conditions": "HER2-positive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "SCREENING",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "Spatial transcriptomic analysis",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* HER2 positive breast cancer\n* Stage IV disease\n* Treated with T-Dxd\n* Available FFPE samples\n\nExclusion Criteria:\n\n* TNBC breast cancer\n* Hormone receptor positive breast cancer\n* Non-available FFPE samples\n* Treated except T-Dxd",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}